The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Advantages & uses of machine learning in the prognostication of AML
Shaun Fleming, MBBS, FRACP, FRCPA, Alfred Hospital, Melbourne, Australia, discusses the use of machine learning to prognosticate patients with acute myeloid leukemia (AML), explaining the benefits of this approach. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen – research funding, speakers honoraria, advisory board membership
Gilead – advisory board membership
Novartis – speakers honorarium
BMS – advisory board membership, speakers honorarium
Pfizer – advisory board membership, speakers honorarium
